Page 138 - DUOKOPT BIBLIOBOOK

MONOPROST - bibliography book - CONFIDENTIAL - document for exclusive use by personnel of Laboratoires Théa – DO NOT DISTRIBUTE
®

KEY MESSAGES

X A 5-year study comparing effects of Dorzolamide/Timolol vs Brinzolamide/Timolol.

STRENGTHS

X Dorzolamide significantly increases haemodynamic parameters in retrobulbar vessels.
There is increasing evidence that a reduced ocular blood flow is directly associated with
VF loss.

X The results shows a significantly lower rates of VF progression at 5 years in POAG eyes
treated with dorzolamide–timolol compared with eyes treated with brinzolamide–
timolol.

WEAKNESSES

X The inclusion of both eyes in the analysis. Previous authors described a between-eye
correlation in progression of VF damage in glaucomatous eyes; these observations were
anecdotal or were of borderline statistical significance.

X Progression end-points based on VF criteria have been highly controversial.

MARKETING CLAIM

X Treatment with Dorzolamide-Timolol reduces the risk of visual field progression.

138